Table 4.
Cancer drug target genes which are differentially regulated between tumor-matched norms and autopsy-derived “healthy” tissue norms at the level of pan-cancer comparison.
| Drug target gene ID | Up/down-regulated in tumor adjacent norms | Cancer drug generic names | Approved cancer types |
|---|---|---|---|
| TUBA1C | Up | Ado-trastuzumab emtansine, enfortumab vedotin, vinblastine, vincristine, vindesine, vinorelbine | Breast cancer, non-small cell lung cancer (NSCLC), bladder cancer, ovarian cancer |
| IDH1 | Up | Ivosidenib | Acute myeloid leukemia |
| NFKB1 | Up | Thalidomide | Multiple myeloma |
| TUBB4B | Up | Cabazitaxel, docetaxel, eribulin, ixabepilone, paclitaxel | Prostate cancer, bladder cancer, breast cancer, NSCLC, ovarian cancer, stomach cancer, endometrial cancer, cervical cancer, kidney cancer |
| CSF1R | Up | Dovitinib, sunitinib | Kidney cancer, thyroid cancer |
| PSMB5 | Up | Bortezomib, carfilzomib, ixazomib (MLN9708) | Multiple myeloma |
| HDAC2 | Up | Belinostat, panobinostat, romidepsin, vorinostat | T-cell lymphoma, multiple myeloma |
| TUBB | Up | Ado-trastuzumab emtansine, brentuximab vedotin, cabazitaxel, docetaxel, enfortumab vedotin, eribulin, ixabepilone, paclitaxel, Vinblastine, Vincristine, Vindesine, Vinorelbine | Breast cancer, NSCLC, prostate cancer, bladder cancer, ovarian cancer, stomach cancer, endometrial cancer, cervical cancer, kidney cancer |
| IDH2 | Up | enasidenib | Acute Myeloid Leukemia |
| TUBA1B, TUBA4A | Up | Ado-trastuzumab emtansine, brentuximab vedotin, enfortumab vedotin, vinblastine, vincristine, vindesine, vinorelbine | Breast cancer, NSCLC, bladder cancer, ovarian cancer |
| CDK4 | Up | Abemaciclib (LY2835219), flavopiridol (alvocidib), palbociclib, ribociclib | Breast cancer |
| LYN | Up | Masitinib | Pancreatic cancer, melanoma, multiple myeloma, peripheral T-cell lymphoma, gastrointestinal stromal tumor, gastric cancer, colorectal cancer, esophageal cancer |
| ERBB2 | Up | Ado-trastuzumab emtansine, afatinib, lapatinib, pertuzumab, trastuzumab | Breast cancer, NSCLC, stomach cancer, endometrial cancer |
| FGFR1 | Down | Dovitinib, erdafitinib, lenvatinib, nintedanib (BIBF 1120), regorafenib, sorafenib | Bladder cancer, kidney cancer, hepatocellular carcinoma, thyroid cancer, colorectal cancer, ovarian cancer |
| MAPK11 | Down | Regorafenib | Colorectal cancer, hepatocellular carcinoma |
| PGF | Down | Aflibercept | Colorectal cancer |
| ABL1 | Down | Bosutinib, dasatinib, imatinib, nilotinib, ponatinib, regorafenib | Colorectal cancer, hepatocellular carcinoma |
| FLT4 | Down | Axitinib, dovitinib, foretinib, lenvatinib, nintedanib (BIBF 1120), pazopanib, regorafenib, sorafenib, sunitinib, tivozanib, vandetanib | Kidney cancer, thyroid cancer, hepatocellular carcinoma, colorectal cancer, ovarian cancer, NSCLC |
| PDGFRA | Down | Imatinib, lenvatinib, masitinib, midostaurin, nintedanib (BIBF 1120), olaratumab, pazopanib, regorafenib, sunitinib, tivozanib | Kidney cancer, hepatocellular carcinoma, thyroid cancer, colorectal cancer |
| TUBB3 | Down | Ado-Trastuzumab Emtansine, Brentuximab vedotin, Cabazitaxel, Enfortumab vedotin, Eribulin, Ixabepilone, Vinblastine, Vincristine, Vindesine | Breast cancer, NSCLC, prostate cancer, bladder cancer |
| HDAC4 | Down | Belinostat, Vorinostat | T-cell lymphoma |
| NTRK3 | Down | Entrectinib, Larotrectinib | Pan-cancer |
| RARG | Down | Acitretin, Alitretinoin, Tretinoin | Nonmelanoma skin cancers (chemoprevention), Kaposi’s sarcoma |
| PDGFRB | Down | Dovitinib, Imatinib, Lenvatinib, Masitinib, Midostaurin, Nintedanib (BIBF 1120), Pazopanib, Regorafenib, Sorafenib, Sunitinib, Tivozanib | Kidney cancer, Hepatocellular carcinoma, thyroid cancer, colorectal cancer, ovarian cancer |
| HDAC7 | Down | Belinostat | T-cell lymphoma |